Patient Reported Outcomes inVestigation Following Initiation of Drug Therapy With Entresto (Sacubitril/Valsartan) in Heart Failure

Overview

About this study

Real-world evidence of the clinical course of patient symptoms following initiation of sacubitril/valsartan via PROs with a patient-centered study design will provide important evidence of potentially beneficial outcomes associated with the use of this therapy.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

Diagnosis of chronic systolic HF
Active care by a provider in a healthcare system connected to a PCORnet data partner
Ability to speak and read English (given the use of the English ePRO technology)
Newly initiating sacubitril/valsartan (observational sacubitril/valsartan treatment group only - within 1 week of first dose)
At least a 25% change ACE/ARB dose in the last 6 months (comparator group only)
Reliable access to the internet

Exclusion Criteria:

Inability to provide informed consent
Life expectancy < 6 months
For comparator group patients: Physician documentation of planned initiation of sacubitril/valsartan within 12 weeks

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location	Status
Rochester, Minn. Mayo Clinic principal investigator Shannon Dunlay, M.D., M.S.	Closed for enrollment

Mayo Clinic Location

Status

Rochester, Minn.

Mayo Clinic principal investigator

Shannon Dunlay, M.D., M.S.

Closed for enrollment

More information

Publications

Publications are currently not available

Clinical Trials